MicroPort® and U&I Corporation Signs Cooperation Agreement
Shanghai, China – On August 18, Shanghai MicroPort Medical (Group) Co., Ltd. ("MicroPort®") entered into a cooperation agreement with a South Korean company U&I Corporation. The signing ceremony took place in MicroPort® Shanghai headquarters. Dr. Linda Lin, First Vice President of MicroPort® International Business, and Koo Ja-Kyo, Chief Executive Officer ("CEO") of U&I Corporation, attended the ceremony and signed the agreement on behalf of the two companies.
During the ceremony, Dr. Linda Lin said: "I have full confidence in the cooperation between MicroPort® and U&I Corporation. MicroPort® has diversified product portfolio and covers main markets including Asia-Pacific, Europe, and America. As a major economy in Asia, South Korea is no wonder an important target market of MicroPort® and we hope to serve local patients with high-quality and high-end medical devices. Based on the win-win principle, it is expected that this partnership will help us to further expand the market. "
Founded in 1993, U&I Corporation is a technology-oriented company focused on developing and manufacturing high-tech products such as degradable new material and pain management devices. In 2015, U&I Corporation was listed in South Korea's KOSDAQ (stock code: 056090). Currently, U&I Corporation's products are approved for use in around 30 countries of the world with high market recognition. This partnership will further diversity the product portfolio of U&I Corporation, and will facilitate MicroPort® to introduce its latest technology and products to the South Korea market.
U&I Corporation CEO Koo Ja-Kyo said: "U&I Corporation is dedicated to providing better service to patients. I think this ceremony marks a good starting point of our cooperation which may lead to deeper collaboration in the South Korea market in the future. U&I Corporation will work closely with MicroPort® to provide help to more patients."
Currently, MicroPort®'s new-generation drug-eluting stent Firehawk® Rapamycin Target Eluting Coronary Stent System ("Firehawk®") and Firefighter™ PTCA Balloon Catheter ("Firefighter™") obtained regulatory approval in the South Korea market. This partnership with U&I Corporation will lay a solid foundation for MicroPort® to further expand the South Korea market and will promote the overall development of the company's international business as well. MicroPort® will make the best use of this opportunity to bring more high-quality and high-end medical device to South Korea to benefit local patients.
Privacy settings
This website may store cookies on your browser. Cookies are mostly used to make the website work as you expect it to. No cookie will directly identify you, but it can give you a more personalized browsing experience.
MicroPort respects your privacy rights, so you can block some types of cookies. Technically non-essential cookies and tracking mechanisms, that enable us to provide you with customized offers (marketing cookies), are only used if you have given prior consent to such use.
By clicking “Save”, only the cookies you selected will be used. You can withdraw the consent that you granted here at any time by going to Cookies Settings.
For more information, please see our Cookie Policy.